Clinical Trial

AERIAL Trial: Antiplatelet Therapy in Heart Transplantation

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Cardiac allograft vasculopathy is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. The research team is investigating whether early antiplatelet therapy post heart transplant can prevent the development of CAV. This study will determine the feasibility of a large multicenter randomized placebo-controlled trial to answer this question.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-02-22; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2022-01-12
Trial Details
NCT Number NCT04770012
Lead Sponsor Ottawa Heart Institute Research Corporation
Collaborators: Canadian Institutes of Health Research (CIHR)
Conditions Cardiac Allograft Vasculopathy, Heart Transplant
Enrollment 135 participants
Start Date 2021-06-28
Primary Completion 2027-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-06